Orphazyme A/S (ORPH) Sinks 54% on CRL
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Orphazyme A/S (NASDAQ: ORPH) sinks 54% in pre-open trading announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C (NPC).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sol-Gel Technologies Ltd. (SLGL) Announces Approval of TWYNEO
- Petros Pharmaceuticals, Inc (PTPI) Granted FDA Meeting to Discuss Label Expansion of STENDRA®
- SGOCO Group (SGOC) Halted on Second LUDP, Up 30%
Create E-mail Alert Related CategoriesFDA, Momentum Movers, Trader Talk
Related EntitiesPre Market Movers, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!